Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Journal Article

Local Library Link: Find It @ Loyola

Authors: Al-Mansour, Z; Li, H; Cook, JR; Constine, LS; Couban, S; Stewart, DA; Shea, TC; Porcu, P; Winter, JN; Kahl, BS; Smith, SM; Marcellus, DC; Barton, KP; Mills, GM; LeBlanc, M; Rimsza, LM; Forman, SJ; Leonard, JP; Fisher, RI; Friedberg, JW; Stiff, PJ
Article Title: Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.
Abstract: Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility (?=?1), choice (?=?2), or progression (?=?9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (?=?.56), and 40% vs. 45% (?=?.98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.
Journal Title: Leukemia lymphoma
ISSN: 1029-2403; 1026-8022
Publisher: Unknown  
Date Published: 2019